These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 4799943)

  • 21. A rapid spectrophotometric assay of phenylpyruvate oxidase activity.
    Goodwin BL; Werner EG
    Anal Biochem; 1972 Nov; 50(1):180-6. PubMed ID: 5080724
    [No Abstract]   [Full Text] [Related]  

  • 22. Effect of vitamin B 6 on levodopa-induced changes in spinal fluid homovanillic acid.
    Klawans HL
    J Neurol Sci; 1971 Dec; 14(4):421-6. PubMed ID: 5125757
    [No Abstract]   [Full Text] [Related]  

  • 23. Metabolism of 3,4-dihydroxyphenylalanine (L-dopa) in human subjects.
    Goodall M; Alton H
    Biochem Pharmacol; 1972 Sep; 21(17):2401-8. PubMed ID: 4647074
    [No Abstract]   [Full Text] [Related]  

  • 24. Metabolism of dopa in Parkinsonism.
    Sandler M; Karoum F; Ruthven CR
    N Engl J Med; 1969 Dec; 281(25):1429. PubMed ID: 5355467
    [No Abstract]   [Full Text] [Related]  

  • 25. Physiologic, biochemical, and pathological backgrounds of levodopa and possibilities for the future.
    Hornykiewicz OD
    Neurology; 1970 Dec; 20(12):1-5. PubMed ID: 5531292
    [No Abstract]   [Full Text] [Related]  

  • 26. Sensitive fluorescence monitoring of aromatic acids after anion-exchange chromatography of body fluids.
    Katz S; Pitt WW; Jones G
    Clin Chem; 1973 Aug; 19(8):817-20. PubMed ID: 4720807
    [No Abstract]   [Full Text] [Related]  

  • 27. Concerning the mechanism of action of L-DOPA in Parkinsonism.
    Proctor P
    Biochem Med; 1970 Nov; 4(3):357-9. PubMed ID: 5524076
    [No Abstract]   [Full Text] [Related]  

  • 28. L-dopa and cerebrospinal fluid homovanillic acid in Parkinsonism.
    Weiner W; Harrison W; Klawans H
    Life Sci; 1969 Sep; 8(17):971-6. PubMed ID: 5808572
    [No Abstract]   [Full Text] [Related]  

  • 29. Responses of the urinary excretion of homovanillic acid and of 5-hydroxy-indol-acetic acid to treatment with L-dopa and amantadine.
    Molnár G; Fodor A
    Ther Hung; 1973; 21(1):35-40. PubMed ID: 4792890
    [No Abstract]   [Full Text] [Related]  

  • 30. Urinary excretion of dopamine and homovanillic acid during L-dopa treatment of Parkinson's disease.
    Streifler M; Vardi Y; Kesten M; Oberman Z; Herzberg M
    Isr J Med Sci; 1972 May; 81(5):597-601. PubMed ID: 5042950
    [No Abstract]   [Full Text] [Related]  

  • 31. [Study of 3-4-dihydroxyphenylacetic acid, a dopamine catabolite, in patients with Parkinson's disease before treatment with L-dopa].
    Samson M; Bohuon C; Augustin P; Comoy E; Pouliquen A
    Rev Neurol (Paris); 1972 Aug; 127(2):315-7. PubMed ID: 4666641
    [No Abstract]   [Full Text] [Related]  

  • 32. m-Hydroxyphenylacetic acid formation from L-dopa in man: suppression by neomycin.
    Sandler M; Karoum F; Ruthven CR; Calne DB
    Science; 1969 Dec; 166(3911):1417-8. PubMed ID: 5350345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Studies on chemiluminescence in the enzymatic and autoxidative transformation of 3,4-dihydroxyphenylalanine into eumelanins.
    Villablanca M; Indig G; Slawinska D; Slawinski J
    J Biolumin Chemilumin; 1989; 3(4):181-90. PubMed ID: 2508433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis in human plasma of 3-methoxytyrosine: a metabolite of DOPA.
    Fellman JH; Joyce JR; Strandholm JJ
    Clin Chim Acta; 1971 Apr; 32(2):313-5. PubMed ID: 5122233
    [No Abstract]   [Full Text] [Related]  

  • 35. Linoleate oxidation induced by lipoxygenase and heme proteins: a direct spectrophotometric assay.
    Ben-Aziz A; Grossman S; Ascarelli I; Budowski P
    Anal Biochem; 1970 Mar; 34():88-100. PubMed ID: 5462381
    [No Abstract]   [Full Text] [Related]  

  • 36. The effect of antacid administration on the absorption and metabolism of levodopa.
    Leon AS; Spiegel HE
    J Clin Pharmacol New Drugs; 1972 Jul; 12(7):263-7. PubMed ID: 4483533
    [No Abstract]   [Full Text] [Related]  

  • 37. L-dopa in Parkinson's disease. A report on 95 cases and review of the literature.
    Lewis I
    J Med Assoc State Ala; 1971 May; 40(11):709-18. PubMed ID: 5573008
    [No Abstract]   [Full Text] [Related]  

  • 38. Absorption and metabolism of levodopa.
    Abrams WB; Coutinho CB; Leon AS; Spiegel HE
    JAMA; 1971 Dec; 218(13):1912-4. PubMed ID: 5171067
    [No Abstract]   [Full Text] [Related]  

  • 39. Parkinson's disease: from brain homogenate to treatment.
    Hornykiewicz O
    Fed Proc; 1973 Feb; 32(2):183-90. PubMed ID: 4143953
    [No Abstract]   [Full Text] [Related]  

  • 40. Variation of levodopa metabolism with gastrointestinal absorption site.
    Sandler M; Ruthven CR; Goodwin BL; Hunter KR; Stern GM
    Lancet; 1974 Feb; 1(7851):238-40. PubMed ID: 4130247
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.